ClinicalTrials.gg
CompletedNCT05623839Updated Jul 5, 2023

A Study of LY3305677 in Participants With Obesity Or Overweight

A Phase 1 interventional study of LY3305677 and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-05.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.

Enrollment
20th of 22
32 · median 187
Started
2022
with 1 other
Phase 1
3 of 22
none open now
Registered
5th of 22
by date
Lead sponsor
3 of 22
Eli Lilly and Company

Among the 22 studies testing mazdutide in Obesity, this one is the 20th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1, and was the 5th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing mazdutide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

This study's enrollment of 32 is below the median of 67 across 9,027 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation
  • Participants with stable weight for 3 months and of 27.0 and 50.0 kilograms per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have history of type 1 diabetes mellitus or type 2 diabetes mellitus, ketoacidosis, or hyperosmolar state or coma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    LY3305677

    LY3305677 administered subcutaneously (SC)

    Drug: LY3305677

  • Placebo comparator
    Placebo

    Placebo administered SC

    Drug: Placebo

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

07

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through Week 20

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3305677

    PK: Cmax of LY3305677

    Time frame: Predose up to 72 hours postdose

  2. PK: Area Under the Concentration Versus Time Curve (AUC) of LY3305677

    PK: AUC of LY3305677

    Time frame: Predose up to 72 hours postdose

  3. Pharmacodynamics (PD): Percentage change in Body Weight

    PD: Percentage change in Body Weight

    Time frame: Baseline through Week 20

08

Study locations

3 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
  • ICON Early Phase Services Lenexa Center
    Salt Lake City, Utah 84124, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jun 2023, 7 months.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2022
First posted
Nov 21, 2022
StartActual
Nov 16, 2022
Primary completionActual
Jun 27, 2023
CompletionActual
Jun 27, 2023
Last update
Jul 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05623839
Responsible party
Sponsor
First posted
Nov 21, 2022
Start date
Nov 16, 2022
Primary completion
Jun 27, 2023
Completion
Jun 27, 2023
Last update
Jul 5, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion